Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 3
1970 4
1971 3
1972 3
1973 2
1974 4
1975 3
1976 4
1977 5
1978 4
1979 4
1980 2
1981 4
1982 4
1983 6
1984 6
1985 10
1986 9
1987 12
1988 6
1989 5
1990 8
1991 15
1992 13
1993 14
1994 23
1995 19
1996 27
1997 29
1998 33
1999 30
2000 28
2001 39
2002 30
2003 38
2004 45
2005 54
2006 42
2007 61
2008 71
2009 69
2010 77
2011 106
2012 100
2013 112
2014 139
2015 106
2016 90
2017 100
2018 125
2019 117
2020 123
2021 101
2022 70
2023 77
2024 29

Text availability

Article attribute

Article type

Publication date

Search Results

1,995 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Digestive System Carcinoma"
Page 1
Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
Oura K, Morishita A, Tani J, Masaki T. Oura K, et al. Int J Mol Sci. 2021 May 28;22(11):5801. doi: 10.3390/ijms22115801. Int J Mol Sci. 2021. PMID: 34071550 Free PMC article. Review.
Liver cancer has the fourth highest mortality rate of all cancers worldwide, with hepatocellular carcinoma (HCC) being the most prevalent subtype. Despite great advances in systemic therapy, such as molecular-targeted agents, HCC has one of the worst prognoses due to drug …
Liver cancer has the fourth highest mortality rate of all cancers worldwide, with hepatocellular carcinoma (HCC) being the most preva …
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, Moehler M; CheckMate 577 Investigators. Kelly RJ, et al. N Engl J Med. 2021 Apr 1;384(13):1191-1203. doi: 10.1056/NEJMoa2032125. N Engl J Med. 2021. PMID: 33789008 Clinical Trial.
METHODS: We conducted CheckMate 577, a global, randomized, double-blind, placebo-controlled phase 3 trial to evaluate a checkpoint inhibitor as adjuvant therapy in patients with esophageal or gastroesophageal junction cancer. ...The maximum duration of the trial …
METHODS: We conducted CheckMate 577, a global, randomized, double-blind, placebo-controlled phase 3 trial to evaluate a checkp …
Ampullary cancer: an overview.
Ahn DH, Bekaii-Saab T. Ahn DH, et al. Am Soc Clin Oncol Educ Book. 2014:112-5. doi: 10.14694/EdBook_AM.2014.34.112. Am Soc Clin Oncol Educ Book. 2014. PMID: 24857067 Free PMC article. Review.
Because of their earlier presentation, resection rates for all patients are much higher than other periampullary carcinomas. Moreover, their prognosis tends to be better than those with other periampullary- and pancreatic-originating cancers. ...Herein, we provide an overv …
Because of their earlier presentation, resection rates for all patients are much higher than other periampullary carcinomas. Moreover …
The Landmark Series: Hilar Cholangiocarcinoma.
Soares KC, Jarnagin WR. Soares KC, et al. Ann Surg Oncol. 2021 Aug;28(8):4158-4170. doi: 10.1245/s10434-021-09871-6. Epub 2021 Apr 7. Ann Surg Oncol. 2021. PMID: 33829358 Free PMC article. Review.
As such, the data driving the management of this disease generally are not based on prospective clinical trial data but rather consist of retrospective experiences and limited level 1 data. Surgical resection offers the best chance of a long-term survival, but local …
As such, the data driving the management of this disease generally are not based on prospective clinical trial data but rather …
Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial.
Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J; Japan Clinical Oncology Group (JCOG). Morizane C, et al. JAMA Oncol. 2022 Oct 1;8(10):1447-1455. doi: 10.1001/jamaoncol.2022.3395. JAMA Oncol. 2022. PMID: 35980649 Free PMC article. Clinical Trial.
IMPORTANCE: Etoposide plus cisplatin (EP) and irinotecan plus cisplatin (IP) are commonly used as community standard regimens for advanced neuroendocrine carcinoma (NEC). OBJECTIVE: To identify whether EP or IP is a more effective regimen in terms of overall survival (OS) …
IMPORTANCE: Etoposide plus cisplatin (EP) and irinotecan plus cisplatin (IP) are commonly used as community standard regimens for advanced n …
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
Subbiah V, Iannotti NO, Gutierrez M, Smith DC, Féliz L, Lihou CF, Tian C, Silverman IM, Ji T, Saleh M. Subbiah V, et al. Ann Oncol. 2022 May;33(5):522-533. doi: 10.1016/j.annonc.2022.02.001. Epub 2022 Feb 14. Ann Oncol. 2022. PMID: 35176457 Free article. Clinical Trial.
Overall, 12 partial responses were achieved, most commonly in cholangiocarcinoma (n = 5) as well as in a broad spectrum of tumors including head and neck, pancreatic, gallbladder, uterine, urothelial carcinoma, recurrent pilocytic astrocytoma, and non-small-cell lun …
Overall, 12 partial responses were achieved, most commonly in cholangiocarcinoma (n = 5) as well as in a broad spectrum of tumors including …
Cholangiocarcinoma Therapeutics: An Update.
Nguyen MLT, Toan NL, Bozko M, Bui KC, Bozko P. Nguyen MLT, et al. Curr Cancer Drug Targets. 2021;21(6):457-475. doi: 10.2174/1568009621666210204152028. Curr Cancer Drug Targets. 2021. PMID: 33563168 Review.
Besides screening for operable individuals, efficacious therapeutic for recurrent and advanced CCA is urgently needed. The treatment outcome of available therapeutics is important to clarify clinical indication and facilitate the development of treatment strategies. …
Besides screening for operable individuals, efficacious therapeutic for recurrent and advanced CCA is urgently needed. The treatment …
AGA Clinical Practice Update on Endoscopic Treatment of Barrett's Esophagus With Dysplasia and/or Early Cancer: Expert Review.
Sharma P, Shaheen NJ, Katzka D, Bergman JJGHM. Sharma P, et al. Gastroenterology. 2020 Feb;158(3):760-769. doi: 10.1053/j.gastro.2019.09.051. Epub 2019 Nov 12. Gastroenterology. 2020. PMID: 31730766 Review.
In case of complete endoscopic eradication, the neosquamous mucosa and the gastric cardia are sampled by 4-quadrant biopsies. BEST PRACTICE ADVICE 10: If random biopsies obtained from the neosquamous epithelium demonstrate intestinal metaplasia/dysplasia or subsquamous int …
In case of complete endoscopic eradication, the neosquamous mucosa and the gastric cardia are sampled by 4-quadrant biopsies. BEST PRACTICE …
Intrathoracic vs Cervical Anastomosis After Totally or Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer: A Randomized Clinical Trial.
van Workum F, Verstegen MHP, Klarenbeek BR, Bouwense SAW, van Berge Henegouwen MI, Daams F, Gisbertz SS, Hannink G, Haveman JW, Heisterkamp J, Jansen W, Kouwenhoven EA, van Lanschot JJB, Nieuwenhuijzen GAP, van der Peet DL, Polat F, Ubels S, Wijnhoven BPL, Rovers MM, Rosman C; ICAN collaborative research group. van Workum F, et al. JAMA Surg. 2021 Jul 1;156(7):601-610. doi: 10.1001/jamasurg.2021.1555. JAMA Surg. 2021. PMID: 33978698 Free PMC article. Clinical Trial.
OBJECTIVE: To compare an intrathoracic with a cervical anastomosis in a randomized clinical trial. DESIGN, SETTING, AND PARTICIPANTS: This open, multicenter randomized clinical superiority trial was performed at 9 Dutch high-volume hospit …
OBJECTIVE: To compare an intrathoracic with a cervical anastomosis in a randomized clinical trial. DESIGN, SETTING, AND …
Multidisciplinary Therapy of Esophageal Cancer.
Egyud MR, Tseng JF, Suzuki K. Egyud MR, et al. Surg Clin North Am. 2019 Jun;99(3):419-437. doi: 10.1016/j.suc.2019.02.002. Epub 2019 Mar 30. Surg Clin North Am. 2019. PMID: 31047033 Review.
Response to induction therapy is an important prognostic marker. For esophageal squamous cell carcinoma, it may be acceptable to observe clinical complete responders after chemoradiotherapy and perform salvage esophagectomy for recurrent disease. Clinical …
Response to induction therapy is an important prognostic marker. For esophageal squamous cell carcinoma, it may be acceptable to obse …
1,995 results